Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
RESEARCH TOOLSreports
| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 17.45M | $ 25.82M | $ 57.03M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 15.85M | $ 24.86M | $ 54.95M | $ -246.00K | $ -74.00K |
| Operating Income | $ -143.16M | $ -62.71M | $ -12.16M | $ -27.00M | $ -4.30M |
| EBITDA | $ -131.67M | $ -59.11M | $ -13.17M | $ -26.56M | $ -4.55M |
| Net Income | $ -135.89M | $ -62.09M | $ -13.83M | $ -26.81M | $ -4.67M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 227.44M | $ 217.03M | $ 171.81M | $ 168.13M | $ 57.95M |
| Total Assets | $ 265.49M | $ 227.86M | $ 178.91M | $ 171.97M | $ 58.32M |
| Total Debt | $ 31.73M | $ 20.16M | $ 1.89M | $ 831.00K | $ 164.00K |
| Net Debt | $ -193.22M | $ -51.51M | $ -169.44M | $ -167.30M | $ -57.79M |
| Total Liabilities | $ 68.50M | $ 34.96M | $ 12.18M | $ 5.99M | $ 64.32M |
| Stockholders' Equity | $ 196.99M | $ 192.90M | $ 166.73M | $ 165.98M | $ -6.00M |
| Cash Flow | |||||
| Free Cash Flow | $ -123.00M | $ -49.54M | $ 3.16M | $ -21.59M | $ -3.85M |
| Operating Cash Flow | $ -117.49M | $ -49.03M | $ 3.75M | $ -21.14M | $ -3.67M |
| Investing Cash Flow | $ 140.60M | $ -144.63M | $ -586.00K | $ -456.00K | $ -175.00K |
| Financing Cash Flow | $ 130.18M | $ 93.99M | $ 21.00K | $ 131.77M | $ 59.45M |